Polyarteritis nodosa

Nicolò Pipitone, Carlo Salvarani

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Polyarteritis nodosa (PAN) is a rare vasculitis affecting middle-sized arteries. Its annual incidence in Europe is estimated to range between 0 and 1.6 cases per million, while the prevalence is about 31 cases per million. The frequency of hepatitis B virus (HBV)-related PAN has declined in developed countries since vaccination against HBV has been implemented. Specifically, before vaccination against HBV was implemented on a large scale, more than one-third of adults with PAN were infected by HBV, whereas currently only 5 % of European adults with PAN are infected by HBV. PAN is usually considered an immune-complex-driven vasculitis. However, the evidence of abundant CD4+ T cells in vascular inflammatory infiltrates suggests that PAN may also be induced by a T-cell response. Clinically, PAN usually presents with constitutional manifestations as well as symptoms and signs related to the organs affected. Organ ischemia is thought to be due to vascular stenoses, while ruptured aneurysms can result in tissue hemorrhage. The most frequent clinical features include constitutional manifestations, myalgia, arthralgia, peripheral neuropathy and mononeuritis multiplex. There are no specific blood tests to diagnose PAN, but inflammatory markers are typically elevated. Therefore, the diagnosis rests on histological changes in affected organs, showing a transmural vessel wall infiltrate, or angiographic findings, including small saccular or fusiform aneurysms and stenoses. Treatment includes glucocorticoids in patients without poor prognostic factors or cyclophosphamide if the disease is life- or organ-threatening.

Original languageEnglish
Title of host publicationSystemic Vasculitides
Subtitle of host publicationCurrent Status and Perspectives
PublisherSpringer International Publishing
Pages189-196
Number of pages8
ISBN (Electronic)9783319401362
ISBN (Print)9783319401348
DOIs
Publication statusPublished - Jan 1 2016

Fingerprint

Polyarteritis Nodosa
Hepatitis B virus
Vasculitis
Aneurysm
Blood Vessels
Pathologic Constriction
Vaccination
Mononeuropathies
T-Lymphocytes
Ruptured Aneurysm
Myalgia
Arthralgia
Hematologic Tests
Peripheral Nervous System Diseases
Antigen-Antibody Complex
Developed Countries
Cyclophosphamide
Glucocorticoids
Signs and Symptoms
Ischemia

ASJC Scopus subject areas

  • Medicine(all)
  • Immunology and Microbiology(all)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Pipitone, N., & Salvarani, C. (2016). Polyarteritis nodosa. In Systemic Vasculitides: Current Status and Perspectives (pp. 189-196). Springer International Publishing. https://doi.org/10.1007/978-3-319-40136-2_16

Polyarteritis nodosa. / Pipitone, Nicolò; Salvarani, Carlo.

Systemic Vasculitides: Current Status and Perspectives. Springer International Publishing, 2016. p. 189-196.

Research output: Chapter in Book/Report/Conference proceedingChapter

Pipitone, N & Salvarani, C 2016, Polyarteritis nodosa. in Systemic Vasculitides: Current Status and Perspectives. Springer International Publishing, pp. 189-196. https://doi.org/10.1007/978-3-319-40136-2_16
Pipitone N, Salvarani C. Polyarteritis nodosa. In Systemic Vasculitides: Current Status and Perspectives. Springer International Publishing. 2016. p. 189-196 https://doi.org/10.1007/978-3-319-40136-2_16
Pipitone, Nicolò ; Salvarani, Carlo. / Polyarteritis nodosa. Systemic Vasculitides: Current Status and Perspectives. Springer International Publishing, 2016. pp. 189-196
@inbook{296636b31e85490c9e7413bd104ebe90,
title = "Polyarteritis nodosa",
abstract = "Polyarteritis nodosa (PAN) is a rare vasculitis affecting middle-sized arteries. Its annual incidence in Europe is estimated to range between 0 and 1.6 cases per million, while the prevalence is about 31 cases per million. The frequency of hepatitis B virus (HBV)-related PAN has declined in developed countries since vaccination against HBV has been implemented. Specifically, before vaccination against HBV was implemented on a large scale, more than one-third of adults with PAN were infected by HBV, whereas currently only 5 {\%} of European adults with PAN are infected by HBV. PAN is usually considered an immune-complex-driven vasculitis. However, the evidence of abundant CD4+ T cells in vascular inflammatory infiltrates suggests that PAN may also be induced by a T-cell response. Clinically, PAN usually presents with constitutional manifestations as well as symptoms and signs related to the organs affected. Organ ischemia is thought to be due to vascular stenoses, while ruptured aneurysms can result in tissue hemorrhage. The most frequent clinical features include constitutional manifestations, myalgia, arthralgia, peripheral neuropathy and mononeuritis multiplex. There are no specific blood tests to diagnose PAN, but inflammatory markers are typically elevated. Therefore, the diagnosis rests on histological changes in affected organs, showing a transmural vessel wall infiltrate, or angiographic findings, including small saccular or fusiform aneurysms and stenoses. Treatment includes glucocorticoids in patients without poor prognostic factors or cyclophosphamide if the disease is life- or organ-threatening.",
author = "Nicol{\`o} Pipitone and Carlo Salvarani",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/978-3-319-40136-2_16",
language = "English",
isbn = "9783319401348",
pages = "189--196",
booktitle = "Systemic Vasculitides",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Polyarteritis nodosa

AU - Pipitone, Nicolò

AU - Salvarani, Carlo

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Polyarteritis nodosa (PAN) is a rare vasculitis affecting middle-sized arteries. Its annual incidence in Europe is estimated to range between 0 and 1.6 cases per million, while the prevalence is about 31 cases per million. The frequency of hepatitis B virus (HBV)-related PAN has declined in developed countries since vaccination against HBV has been implemented. Specifically, before vaccination against HBV was implemented on a large scale, more than one-third of adults with PAN were infected by HBV, whereas currently only 5 % of European adults with PAN are infected by HBV. PAN is usually considered an immune-complex-driven vasculitis. However, the evidence of abundant CD4+ T cells in vascular inflammatory infiltrates suggests that PAN may also be induced by a T-cell response. Clinically, PAN usually presents with constitutional manifestations as well as symptoms and signs related to the organs affected. Organ ischemia is thought to be due to vascular stenoses, while ruptured aneurysms can result in tissue hemorrhage. The most frequent clinical features include constitutional manifestations, myalgia, arthralgia, peripheral neuropathy and mononeuritis multiplex. There are no specific blood tests to diagnose PAN, but inflammatory markers are typically elevated. Therefore, the diagnosis rests on histological changes in affected organs, showing a transmural vessel wall infiltrate, or angiographic findings, including small saccular or fusiform aneurysms and stenoses. Treatment includes glucocorticoids in patients without poor prognostic factors or cyclophosphamide if the disease is life- or organ-threatening.

AB - Polyarteritis nodosa (PAN) is a rare vasculitis affecting middle-sized arteries. Its annual incidence in Europe is estimated to range between 0 and 1.6 cases per million, while the prevalence is about 31 cases per million. The frequency of hepatitis B virus (HBV)-related PAN has declined in developed countries since vaccination against HBV has been implemented. Specifically, before vaccination against HBV was implemented on a large scale, more than one-third of adults with PAN were infected by HBV, whereas currently only 5 % of European adults with PAN are infected by HBV. PAN is usually considered an immune-complex-driven vasculitis. However, the evidence of abundant CD4+ T cells in vascular inflammatory infiltrates suggests that PAN may also be induced by a T-cell response. Clinically, PAN usually presents with constitutional manifestations as well as symptoms and signs related to the organs affected. Organ ischemia is thought to be due to vascular stenoses, while ruptured aneurysms can result in tissue hemorrhage. The most frequent clinical features include constitutional manifestations, myalgia, arthralgia, peripheral neuropathy and mononeuritis multiplex. There are no specific blood tests to diagnose PAN, but inflammatory markers are typically elevated. Therefore, the diagnosis rests on histological changes in affected organs, showing a transmural vessel wall infiltrate, or angiographic findings, including small saccular or fusiform aneurysms and stenoses. Treatment includes glucocorticoids in patients without poor prognostic factors or cyclophosphamide if the disease is life- or organ-threatening.

UR - http://www.scopus.com/inward/record.url?scp=85018077514&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018077514&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-40136-2_16

DO - 10.1007/978-3-319-40136-2_16

M3 - Chapter

AN - SCOPUS:85018077514

SN - 9783319401348

SP - 189

EP - 196

BT - Systemic Vasculitides

PB - Springer International Publishing

ER -